Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Avelumab + Axitinib |
Indication/Tumor Type | renal cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | renal cell carcinoma | predicted - sensitive | Avelumab + Axitinib | Phase III | Actionable | In a Phase III trial (JAVELIN Renal 101), Inlyta (axitinib) plus Bavencio (avelumab) treatment resulted in a median progression-free survival of 13.8 mo. vs. 7.2 mo. with Sutent (sunitinib), and an objective response rate of 55.2% vs. 25.5% with Sutent (sunitinib) in patients with PD-L1-positive renal cell carcinoma, and at median follow-up 13.7% (37) of patients treated with Inlyta (axitinib) plus Bavencio (avelumab) had died vs. 15.2% (44) with Sutent (sunitinib) (PMID: 30779531; NCT02684006). | 30779531 |
PubMed Id | Reference Title | Details |
---|---|---|
(30779531) | Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. | Full reference... |